XOMA Co. (NASDAQ:XOMA) Major Shareholder Bvf Partners L. P/Il Sells 500,742 Shares of Stock

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

XOMA Price Performance

Shares of NASDAQ:XOMA opened at $26.48 on Wednesday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The business’s fifty day moving average price is $28.06 and its two-hundred day moving average price is $28.11. The stock has a market cap of $311.93 million, a PE ratio of -7.61 and a beta of 0.92. XOMA Co. has a one year low of $19.50 and a one year high of $35.00.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.66 million. On average, analysts forecast that XOMA Co. will post -1.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on XOMA shares. HC Wainwright restated a “buy” rating and issued a $123.00 price target on shares of XOMA in a research report on Tuesday, January 7th. StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Thursday, January 16th.

Institutional Investors Weigh In On XOMA

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ellsworth Advisors LLC purchased a new position in shares of XOMA during the third quarter valued at approximately $516,000. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. State Street Corp boosted its holdings in shares of XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Barclays PLC boosted its holdings in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.